The hormone therapy in assisted fertilization cycles: all thanks to a new active principle, now also available in Italy, capable of stimulate the production of oocytes only to the extent necessary, thus lowering i risks of ovarian hyperstimulation and the syndrome associated with it. “For each patient, the hormonal dosage actually needed is calculated thanks to a specific algorithm, which takes into account body weight and anti-Müllerian hormone (AMH) – he explains Antonio La Marca, gynecologist and teacher at the Faculty of Medicine and Surgery of the University of Modena and Reggio Emilia – a personalized approach that improves compliance and reduces hormonal intake where not necessary “.
There international clinical research in which La Marca participated showed that most of the women treated with the new active ingredient had one adequate ovarian response, with better results than traditional therapies. In the cycles of assisted fertilization, the patient is subjected to hormonal treatments that favor the production of oocytes to increase the chances of conception. These are therapies started with standard dosages, which during the course of therapy are adapted according to the individual response. The reaction to ovarian stimulation, in fact, varies from woman to woman and there may be unexpected responses that affect the efficacy and safety of the treatment.
It’s about a carried out as part of the assisted fertilization, because for the first time the clinical modality with which ovarian stimulation is carried out radically changes: if in the previous decades the main variable that guided the doctor in prescribing the drug was the patient’s age, today after several studies it has been understood that there are others variables that affect the most, such as the ovarian reserve. Two women of the same age can have totally different ovarian reserves, and therefore the therapy must be based on different criteria.
“The first advantage of the personalization of care it is certainly the reduced risk for patients, in particular of contracting ovarian hyperstimulation syndrome – explained La Marca – which in the past had an incidence of 4% while today this complication can be almost completely avoided. Another important advantage – concluded La Marca – is the greater possibility of receiving fresh transference, that is, a transfer of embryos a few days after the pick up (the method for taking the oocytes from inside the follicles, so that they can then be fertilized in vitro). Finally, with the new technique, there is also a lower overall consumption of the drug and therefore a reduced health expenditure “.